|
|
 |
 |
 |
|
Ye Xiaoping
MD, PhD, graduated from Nanjin Medical University,
China, and obtained a Ph.D. from Oxford University,
UK. He had worked for more than ten years
in several multinational pharmaceutical companies.
He is familiar with local regulatory rules
regarding pharmaceuticals, and is experienced
in conducting all phases of clinical
trials. He had successfully delivered several
IND and NDA projects. He had been the medical
director of Shanghai Roche Pharmaceutical Ltd.
for six years when he successfully led
numerous global multi-center clinical
trials and local registration trials as well
as Phase IV studies.
Cao Xiaochun MD,
Certified Apothecary, Senior Engineer, graduated
from Zhejiang Traditional Chinese Medical
University. She has more than fifteen years
experiences of drug development during which
she led several projects for drug development
and clinical trials. She is familiar with
local regulatory and drug development procedure.
Xu Jia Lian M.D,
graduated from Shanghai 2nd Medical University,
and obtained a Master’s Degree in Nutrition
Science from Gent University of Belgium. He
has practiced clinical medicine for more than
fifteen years. In addition, he has more than
ten years of experience in R&D departments
in companies including P&U, Lilly and
Shanghai Roche, where he had successfully
led over twenty Phase I to IV local and
global clinical trials.
Shi Xiaoli MD,
graduated with a Master’s Degree from Shanghai
Medical University. She engaged in research
as a post-doctoral fellow for three years
at Scripps Institute in USA. She also has
more than six years of experiences in clinical
trials during which she has supervised multiple
projects including implementing and monitoring
global interferon trials for HBV for three
years at Shanghai Roche Pharmaceuticals.
Gong Yun Jie MD,
graduated from AnHui Medical University. She
has practiced clinical medicine for six years.
Then she engaged in clinical trails at Department
of Medical of Shanghai Roche Pharmaceuticals
for nine years. During that time, she had
acted as a project supervisor responsible
for many international multi-center trials
as well as implementing and monitoring of
local registration trials. In the past three
years, she has involved in projects including
clinical trials quality control, establishing
SOP as well as GCP training. She has also
participated three global audits for
clinical trials conducted in China.
Liu Bo got her bachelor degree from Biochemistry Department, Molecular Biological Division of Jilin University and master degree from Biophysics Department, Life Science College of Peking University. She had worked for Biophysics Institute of Chinese Science College for 2 years, worked for CRO company and multinational pharmaceutical company for 10 years including 6 years experience in Med&Reg Department of Shanghai Roche Pharmaceutical Ltd.
She is familiar with the development of Chinese regulatory affairs and current regulatory regulations, knows well about the requirement of application reading package, and has the ability to communicate with healthy authorities on view of regulation and technical issue well.
Su Binghua graduated
from Shanghai 2nd Medical University. From
1964 to 1967, he was a graduate student of
biostatistics in Xi’an No. 4 Military Medical
University. From 1968 to present, he is a
professor at Department of Biostatistics of
Shanghai 2nd Medical University. From 1990
to 1996, he was a senior visiting scholar
at Department of Biostatistics of Edinburgh
University. From 1995 to present, he has been
a member of expert panel for drug evaluation
committee of SFDA responsible for statistical
analysis of local and global clinical
trials including trial design, DM & SA.
|
|
 |
|
|
Services:
Tigermed Consulting Co., Ltd (www.tigermed.net) is the leading full service Contract Research Organization (CRO) in China, providing regulatory service, Phase I-IV clinical research, biometrics, medical translation and R&D consulting services for drugs, medical devices, diagnostic reagents and functional food products.
Locations:
Headquartered in Shanghai, Tigermed operates in China and the USA, with 15 offices in China and one in the USA.
Quality:
Since our inception in 2002, Tigermed has successfully conducted 110 clinical trials with more than 13,000 subjects enrolled in 339 centers. Our biometrics services comply with US FDA 21 CFR Part 11 requirements and our clinical services comply with ICH GCP.
Expertise:
Tigermed is recognized in therapeutic areas, like Oncology, HBV, Cardiovascular and Vaccine, through our unmatched experience and outstanding achievements in the development of 21 Innovative Drugs (13 NCEs and 8 new biological products), as “The Innovative CRO” in China.
Personnel:
Our management team, most educated in USA or Europe, combines decades of experience working with the world's leading CRO's and drug developers. With a well-trained professional team of more than 100 people and global Standard Operating Procedures (SOPs), Tigermed can provide you with the most professional medical services to help you bring the miracles of your product to market effectively.
|
|
 |
|
|
